Analyst Price Targets — LGND
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 15, 2026 11:29 am | — | RBC Capital | $340.00 | $300.97 | TheFly | Ligand price target raised to $340 from $262 at RBC Capital |
| July 8, 2026 11:06 am | Annabel Samimy | Stifel Nicolaus | $332.00 | $319.43 | TheFly | Ligand price target raised to $332 from $255 at Stifel |
| April 30, 2026 10:09 am | Joseph Pantginis | H.C. Wainwright | $289.00 | $224.86 | TheFly | Ligand price target raised to $289 from $243 at H.C. Wainwright |
| April 28, 2026 11:36 am | — | RBC Capital | $252.00 | $241.79 | TheFly | Ligand price target raised to $252 from $235 at RBC Capital |
| April 27, 2026 6:05 pm | — | Stifel Nicolaus | $255.00 | $241.79 | TheFly | Ligand price target raised to $255 from $230 at Stifel |
| April 14, 2026 2:43 pm | Joseph Pantginis | H.C. Wainwright | $243.00 | $231.11 | TheFly | Ligand price target raised to $243 from $239 at H.C. Wainwright |
| February 24, 2026 4:31 pm | Joseph Pantginis | H.C. Wainwright | $239.00 | $190.86 | TheFly | Ligand price target raised to $239 from $231 at H.C. Wainwright |
| December 10, 2025 12:09 pm | — | Stifel Nicolaus | $230.00 | $185.83 | TheFly | Ligand price target raised to $230 from $220 at Stifel |
| December 10, 2025 11:54 am | Trevor Allred | Oppenheimer | $275.00 | $185.83 | StreetInsider | Oppenheimer Reiterates Outperform Rating on Ligand Pharma (LGND) |
| November 6, 2025 8:07 pm | Annabel Samimy | Stifel Nicolaus | $220.00 | $208.22 | StreetInsider | Ligand Pharma (LGND) PT Raised to $220 at Stifel |
Latest News for LGND
Acquisition adds seven commercial products including VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), and MIPLYFFA® (arimoclomol), and more than 100 development and commercial-stage assets, creating long-term opportunities to drive growth Ligand to provide updated 5-year outlook during Investor Day on December 8, 2026 JUPITER, Fla., July 14, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq:…
EMERYVILLE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation today announced that Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) has completed its previously announced acquisition of XOMA Royalty.
The S&P 500 is up 10.3% YTD, and Wall Street is convinced the markets have more room to run, particularly for this group of stocks we have uncovered. JPMorgan just tagged CECO Environmental (NASDAQ: CECO) with a $130 price target, implying roughly 65% upside from where the stock closed Friday. Bigger and more interesting calls landed on... 5 Stock Setups Where Wall Street Sees the Most Upside Right Now
Ligand Pharmaceuticals has delivered exceptional long-term returns, rising from ~$86 to nearly $300 over six years. Recent developments include a significant Xoma acquisition and portfolio advancements. I closely review LGND's Q1 2026 earnings, highlighting operational and financial performance and strategic moves.
Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset potential dilution to Ligand's common stock upon conversion of the notes JUPITER, Fla., June 25, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today that it completed…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for LGND.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.